Business Description
Ocugen Inc
NAICS : 325412
SIC : 2834
ISIN : US67577C1053
Total Employee Number:
116Description
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.96 | |||||
Equity-to-Asset | 0.1 | |||||
Debt-to-Equity | 5.74 | |||||
Debt-to-EBITDA | -0.52 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -8.52 | |||||
Beneish M-Score | -3.45 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 7.7 | |||||
3-Year EBITDA Growth Rate | 21.3 | |||||
3-Year EPS without NRI Growth Rate | 16.8 | |||||
3-Year FCF Growth Rate | 14.2 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 249.08 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 26.64 | |||||
9-Day RSI | 39.38 | |||||
14-Day RSI | 44.62 | |||||
3-1 Month Momentum % | -37.25 | |||||
6-1 Month Momentum % | -27.68 | |||||
12-1 Month Momentum % | 16.73 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.86 | |||||
Quick Ratio | 1.86 | |||||
Cash Ratio | 1.54 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -12.1 | |||||
Shareholder Yield % | -11.1 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -1483.85 | |||||
Net Margin % | -1605.22 | |||||
EBITDA Margin % | -1432.97 | |||||
FCF Margin % | -1332.78 | |||||
OCF Margin % | -1328.88 | |||||
ROE % | -2220.63 | |||||
ROA % | -129.81 | |||||
ROIC % | -199.63 | |||||
3-Year ROIIC % | 293.51 | |||||
ROC (Joel Greenblatt) % | -447.46 | |||||
ROCE % | -188.51 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 90.67 | |||||
PB Ratio | 80 | |||||
Price-to-Tangible-Book | 59.4 | |||||
EV-to-EBIT | -6.92 | |||||
EV-to-Forward-EBIT | 0.87 | |||||
EV-to-EBITDA | -7.22 | |||||
EV-to-Revenue | 103.43 | |||||
EV-to-Forward-Revenue | 102.63 | |||||
EV-to-FCF | -7.75 | |||||
Price-to-GF-Value | 1.75 | |||||
Earnings Yield (Greenblatt) % | -14.45 | |||||
FCF Yield % | -12.94 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Ocugen Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 3.844 | ||
| EPS (TTM) (€) | -0.206 | ||
| Beta | 1.3001 | ||
| 3-Year Sharpe Ratio | 0.72 | ||
| 3-Year Sortino Ratio | 1.79 | ||
| Volatility % | 68.77 | ||
| 14-Day RSI | 44.62 | ||
| 14-Day ATR (€) | 0.070284 | ||
| 20-Day SMA (€) | 1.2672 | ||
| 12-1 Month Momentum % | 16.73 | ||
| 52-Week Range (€) | 0.8018 - 2.348 | ||
| Shares Outstanding (Mil) | 338.52 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Ocugen Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Ocugen Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-05 08:30 | In 109 days | ||
| Third quarter earnings results for 2026 | 2026-11-05 | In 108 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-31 08:30 | In 12 days | ||
| Second quarter earnings results for 2026 | 2026-07-31 | In 11 days | ||
| Piper SandlVirtual Ophthalmology Day | 2026-07-10 10:00 | 1.26 (-2.63%) | ||
| BIO International Convention | 2026-06-23 11:00 | 1.13 (+0.54%) | ||
| Guidance call for 2026 | 2026-06-13 10:19 | 1.04 (+0.39%) | ||
| General meeting for 2026 | 2026-06-11 08:00 | 1.03 (-3.37%) | ||
| Guidance call for 2026 | 2026-06-04 14:30 | 1.12 (-3.44%) | ||
| Guidance call for 2026 | 2026-05-26 10:30 | 1.15 (-4.01%) |
Show
Entries
Ocugen Inc Frequently Asked Questions
What is Ocugen Inc(STU:2H51)'s stock price today?
The current price of STU:2H51 is €1.19. The 52 week high of STU:2H51 is €2.35 and 52 week low is €0.80.
When is next earnings date of Ocugen Inc(STU:2H51)?
The next earnings date of Ocugen Inc(STU:2H51) is 2026-07-31 Est..
Does Ocugen Inc(STU:2H51) pay dividends? If so, how much?
Ocugen Inc(STU:2H51) does not pay dividend.
Press Release
Articles on Ocugen Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers